share_log

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer KASINGER JAMES R.

SEC announcement ·  Mar 22 17:48
Summary by Moomoo AI
James R. Kasinger, General Counsel and Secretary of CRISPR Therapeutics, has been reported to engage in a transaction involving the company's stock. The action took place on March 20, 2024. However, the announcement did not disclose the type of action, the status, the number of shares involved, the nature of the shares, the transaction price, or the post-transaction shareholding details. Without these specifics, the impact of this event on CRISPR Therapeutics' stock remains unclear to investors.
James R. Kasinger, General Counsel and Secretary of CRISPR Therapeutics, has been reported to engage in a transaction involving the company's stock. The action took place on March 20, 2024. However, the announcement did not disclose the type of action, the status, the number of shares involved, the nature of the shares, the transaction price, or the post-transaction shareholding details. Without these specifics, the impact of this event on CRISPR Therapeutics' stock remains unclear to investors.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more